Orchestration of immune response by innate lymphoid cell subtype 2 at various tumor microenvironment, a suitable target for cancer immunotherapy

References

• Salemme V, Centonze G, Cavallo F, et al. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol 2021;11:610303. doi:10.3389/fonc.2021.610303.
   PubMed Web of Science ®Google Scholar
• Landskron G, de La Fuente M, Thuwajit P, et al. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014;2014:149185. doi:10.1155/2014/149185.
   PubMed Web of Science ®Google Scholar
• Ponomarev A. v, Shubina IZ. Insights into mechanisms of tumor and immune system interaction: association with wound healing. Front Oncol 2019;9:1115. doi:10.3389/fonc.2019.01115.
   PubMed Web of Science ®Google Scholar
• Ducimetière L, Vermeer M, Tugues S. The interplay between innate lymphoid cells and the tumor microenvironment. Front Immunol 2019;10:2895. doi:10.3389/fimmu.2019.02895.
   PubMed Web of Science ®Google Scholar
• Walford HH, Lund SJ, Baum RE, et al. Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness. Clin Immunol 2014;155(1):126–135. doi:10.1016/j.clim.2014.09.007.
   PubMed Web of Science ®Google Scholar
• Jacquelot N, Seillet C, Wang M, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent anti-tumor immunity in melanoma. Nat Immunol 2021;22(7):851–864. doi:10.1038/s41590-021-00943-z.
   PubMed Web of Science ®Google Scholar
• Schuijs MJ, Png S, Richard AC, et al. ILC2-driven innate immune checkpoint mechanism antagonizes NK cell anti-metastatic function in the lung. Nat Immunol 2020;21(9):998–1009. doi:10.1038/s41590-020-0745-y.
   PubMed Web of Science ®Google Scholar
• An Z, Flores-Borja F, Irshad S, et al. Pleiotropic role and bidirectional immunomodulation of innate lymphoid cells in cancer. Front Immunol 2019;10:3111. doi:10.3389/fimmu.2019.03111.
   PubMed Web of Science ®Google Scholar
• Panda SK, Colonna M. Innate lymphoid cells in mucosal immunity. Front Immunol 2019;10:861. doi:10.3389/fimmu.2019.00861.
   PubMed Web of Science ®Google Scholar
• Flamar A-L, Klose CSN, Moeller JB, et al. Interleukin-33 induces the enzyme tryptophan hydroxylase 1 to promote inflammatory group 2 innate lymphoid cell-mediated immunity. Immunity 2020;52(4):606–619.e6. doi:10.1016/j.immuni.2020.02.009.
   PubMed Web of Science ®Google Scholar
• Chuang L-s, Morrison J, Chai Z, et al. The role of group 3 innate lymphoid cells (ILC3) in GM-CSF/CSF2RB-dependent intestinal homeostasis in Crohn’s disease. Inflamm Bowel Dis 2022;28(Supplement_1):S60–S60. doi:10.1093/ibd/izac015.095.
   Google Scholar
• Kansler ER, Li MO. Innate lymphocytes—lineage, localization and timing of differentiation. Cell Mol Immunol 2019;16(7):627–633. doi:10.1038/s41423-019-0211-7.
   PubMed Web of Science ®Google Scholar
• Vivier E, van de Pavert SA, Cooper MD, Belz GT. The evolution of innate lymphoid cells. Nat Immunol 2016;17(7):790–794. doi:10.1038/ni.3459.
   PubMed Web of Science ®Google Scholar
• Zook EC, Kee BL. Development of innate lymphoid cells. Nat Immunol 2016;17(7):775–782. doi:10.1038/ni.3481.
   PubMed Web of Science ®Google Scholar
• Mortha A, Burrows K. Cytokine networks between innate lymphoid cells and myeloid cells. Front Immunol 2018;9:191. doi:10.3389/fimmu.2018.00191.
   PubMed Web of Science ®Google Scholar
• van Beek JJP, Martens AWJ, Bakdash G, de Vries IJM. Innate lymphoid cells in antitumor immunity. J Leukoc Biol 2018;103:479–483.
   Web of Science ®Google Scholar
• Salimi M, Wang R, Yao X, et al. Activated innate lymphoid cell populations accumulate in human tumour tissues. BMC Cancer 2018;18(1):341. doi:10.1186/s12885-018-4262-4.
   PubMedGoogle Scholar
• Schiavoni G, Munitz A, Strid J. Editorial: Emerging Roles for Type 2-Associated Cells and Cytokines in Cancer Immunity. Frontiers Media SA; 2022. doi:10.3389/978-2-88974-075-8.
   Google Scholar
• Wan J, Wu Y, Huang L, et al. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8+ T cells. Cancer Lett 2021;502:34–43. doi:10.1016/j.canlet.2021.01.002.
   PubMed Web of Science ®Google Scholar
• Xiong J, Wang H, He J, Wang Q. Functions of group 2 innate lymphoid cells in tumor microenvironment. Front Immunol 2019;10:1615. doi:10.3389/fimmu.2019.01615.
   PubMed Web of Science ®Google Scholar
• Trabanelli S, Chevalier MF, Martinez-Usatorre A, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun 2017;8(1):593. doi:10.1038/s41467-017-00678-2.
   PubMed Web of Science ®Google Scholar
• Huang Q, et al. Type 2 innate lymphoid cells protect against colorectal cancer progression and predict improved patient survival. Cancers 2021;13:1–16. doi:10.3390/cancers13030559.
   Web of Science ®Google Scholar
• Ding X, Luo Y, Zhang X, et al. IL-33-driven ILC2/eosinophil axis in fat is induced by sympathetic tone and suppressed by obesity. J Endocrinol 2016;231(1):35–48. doi:10.1530/JOE-16-0229.
   PubMed Web of Science ®Google Scholar
• Maggi E, Veneziani I, Moretta L, et al. Group 2 innate lymphoid cells: a double-edged sword in cancer? Cancers 2020;12:1–21. doi:10.3390/cancers12113452.
   Web of Science ®Google Scholar
• Qi J, et al. Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Rep Med 2021;2.
   Google Scholar
• Lok LSC, Walker JA, Jolin HE, et al. Group 2 innate lymphoid cells exhibit tissue-specific dynamic behaviour during type 2 immune responses. Front Immunol 2021;12. doi:10.3389/fimmu.2021.711907.
   PubMed Web of Science ®Google Scholar
• Saranchova I, Han J, Zaman R, et al. Type 2 innate lymphocytes actuate immunity against tumours and limit cancer metastasis. Sci Rep 2018;8(1):2924. doi:10.1038/s41598-018-20608-6.
   PubMedGoogle Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025.
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Munitz A, Strid J. Editorial: emerging roles for type 2-associated cells and cytokines in cancer immunity. Front Immunol 2021;12:811125. doi:10.3389/fimmu.2021.811125.
   PubMed Web of Science ®Google Scholar
• Warner K, Ohashi PS. ILC regulation of T cell responses in inflammatory diseases and cancer. Semin Immunol 2019;41:101284. doi:10.1016/j.smim.2019.101284.
   PubMed Web of Science ®Google Scholar
• Halim TYF, Steer CA, Mathä L, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 2014;40(3):425–435. doi:10.1016/j.immuni.2014.01.011.
   PubMed Web of Science ®Google Scholar
• Jiang M, Cai R, Wang J, et al. ILC2 cells promote Th2 cell differentiation in AECOPD through activated notch-GATA3 signaling pathway. Front Immunol 2021;12:685400. doi:10.3389/fimmu.2021.685400.
   PubMed Web of Science ®Google Scholar
• Mattiola I, Diefenbach A. Enabling anti-tumor immunity by unleashing ILC2. Cell Res 2020;30(6):461–462. doi:10.1038/s41422-020-0330-9.
   PubMed Web of Science ®Google Scholar
• Landskron G, De la Fuente López M, Dubois-Camacho K, et al. Interleukin 33/ST2 axis components are associated to desmoplasia, a metastasis-related factor in colorectal cancer. Front Immunol 2019;10:1394. doi:10.3389/fimmu.2019.01394.
   PubMed Web of Science ®Google Scholar
• Larsen KM, Minaya MK, Vaish V, Peña MMO. The role of IL-33/ST2 pathway in tumorigenesis. Int J Mol Sci 2018;19(9):2676.
   Google Scholar
• Laffont S, Blanquart E, Savignac M, et al. Androgen signaling negatively controls group 2 innate lymphoid cells. J Exp Med 2017;214(6):1581–1592. doi:10.1084/jem.20161807.
   PubMed Web of Science ®Google Scholar
• Chevalier MF, Trabanelli S, Racle J, et al. ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest 2017;127(8):2916–2929. doi:10.1172/JCI89717.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9(3):162–174. doi:10.1038/nri2506.
   PubMed Web of Science ®Google Scholar
• Ercolano G, Gomez-Cadena A, Dumauthioz N, et al. PPARγ drives IL-33-dependent ILC2 pro-tumoral functions. Nat Commun 2021;12(1):2538. doi:10.1038/s41467-021-22764-2.
   PubMed Web of Science ®Google Scholar
• Fan X, Xu Z-B, Li C-L, et al. Mesenchymal stem cells regulate type 2 innate lymphoid cells via regulatory T cells through ICOS-ICOSL interaction. Stem Cells 2021;39(7):975–987. doi:10.1002/stem.3369.
   PubMed Web of Science ®Google Scholar
• Roberts LB, Jowett GM, Read E, et al. MicroRNA-142 critically regulates group 2 innate lymphoid cell homeostasis and function. J Immunol 2021;206(11):2725–2739. doi:10.4049/jimmunol.2000647.
   PubMed Web of Science ®Google Scholar
• Wu L, Lin Q, Ma Z, et al. Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. Leukemia 2020;34(11):3028–3041. doi:10.1038/s41375-020-0843-8.
   PubMed Web of Science ®Google Scholar
• Jacquelot N, et al. Immune checkpoints and innate lymphoid cells—new avenues for cancer immunotherapy. Cancers. 2021;13(23):5967. doi:10.3390/cancers13235967.
   Web of Science ®Google Scholar
• Chung DC, Jacquelot N, Ghaedi M, Warner K, Ohashi PS. Innate lymphoid cells: role in immune regulation and cancer. Cancers. 2022;14:2071. doi:10.3390/cancers14092071.
   PubMed Web of Science ®Google Scholar